Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo Company plc (NYSE: PRGO) has announced the pricing of a registered public offering by its finance subsidiary, Perrigo Finance Unlimited Company. The offering includes $715 million of 6.125% Senior Notes due 2032 and €350 million of 5.375% Senior Notes due 2032. Both notes are priced at 100.000% of their aggregate principal amount.
The notes will be fully guaranteed by Perrigo and its subsidiaries that provide guarantees under Perrigo's credit facilities. Perrigo intends to use the net proceeds to redeem all of its 4.375% Senior Notes Due 2026 and prepay a portion of the Term B Loans outstanding under its credit facilities. The offering is expected to close around September 17, 2024, subject to closing conditions.
Perrigo Company plc (NYSE: PRGO), a global leader in Consumer Self-Care Products, has appointed Charles Atkinson as Executive Vice President, General Counsel and Secretary. Atkinson, with nearly 25 years of experience in the regulated consumer self-care industry, joins Perrigo from Haleon plc, where he served as Interim General Counsel. His expertise includes advising on transactions, integrations, and managing regulated healthcare product lifecycles.
CEO Patrick Lockwood-Taylor expressed confidence in Atkinson's ability to advance Perrigo's vision. Atkinson will replace Todd Kingma, who came out of retirement to serve as Interim EVP, General Counsel & Secretary. Kingma will assist in the transition before resuming his retirement.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced that its President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Piper Sandler Growth Frontiers Conference on Tuesday, September 10 at 10:00 AM CDT. Interested parties can access the webcast on the Perrigo website.
Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions. This presentation at a growth-focused conference suggests that Perrigo may be looking to highlight its expansion strategies and market positioning in the consumer self-care sector.
Perrigo Company plc (NYSE: PRGO) has appointed Dr. David Ball as Executive Vice President and Chief Brand and Digital Officer, a newly created position. Dr. Ball will be responsible for developing an enterprise-wide marketing strategy focusing on consumer needs and brand-building efforts. He brings over 15 years of global consumer goods experience from roles at Bayer Consumer Healthcare and Procter & Gamble.
Dr. Ball's appointment is expected to strengthen Perrigo's global over-the-counter business and support its blended-branded strategy. His unique combination of consumer goods expertise and scientific background (PhD in Biophysics and Genetics) is seen as valuable for innovation and sustainable practices in the company's 135-year history.
Perrigo reported Q2 2024 financial results, with net sales of $1.1 billion, down 10.7% year-over-year. Organic net sales decreased 9.1%, primarily due to lower infant formula sales and reduced demand in Upper Respiratory and Pain & Sleep Aids categories. Adjusted diluted EPS was $0.53, compared to $0.63 in Q2 2023. The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65, despite updating its organic net sales growth outlook to -3% to -1% from the previous +1% to +3%. Perrigo is progressing with its Project Energize efficiency program, targeting $140-$170 million in annualized pre-tax savings by 2026. The company completed the divestment of its HRA Pharma Rare Diseases business on July 10, 2024.
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, has announced a quarterly dividend of $0.276 per share. The dividend is payable on September 17, 2024, to shareholders of record on August 30, 2024. Perrigo is a prominent provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present on Wednesday, August 14 at 3:30 PM EDT.
Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. Perrigo is known for offering over-the-counter (OTC) health and wellness solutions that empower consumers to proactively prevent or treat self-manageable conditions, enhancing individual well-being.
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its plan to release second quarter 2024 financial results on Friday, August 2, 2024. The company will host a conference call at 8:30 A.M. (EST) on the same day. Interested parties can access the earnings conference call via webcast on Perrigo's investor relations website or by phone. A taped replay of the call will be available from approximately 12:00 P.M. (EST) on August 2 until midnight on August 9, 2024.
Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers to proactively prevent or treat self-manageable conditions.
Perrigo Company plc (NYSE PRGO), a leader in Consumer Self-Care Products, has finalized the sale of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total of up to €275 million. The deal includes an upfront cash payment of €190 million with adjustments, and potential earnout payments of up to €85 million based on sales milestones. Proceeds are expected to be used for debt repayment. In 2023, the divested business generated €50 million in net sales and €20 million in adjusted EBITDA. This transaction was anticipated in Perrigo's 2024 financial outlook.
Perrigo Company (NYSE: PRGO), a leader in Consumer Self-Care Products, announced that its President and CEO, Patrick Lockwood-Taylor, along with CFO Eduardo Bezerra, will present at the Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference. The event is scheduled to be held virtually on June 11, 2024, at 1:30 PM EDT. The presentation will be accessible via a webcast on Perrigo's investor relations webpage.